(Q40843326)

24 September 2017

1 reference

title

Peptidomimetic design (English)

1 reference

24 September 2017

Ripka AS

1

1 reference

24 September 2017

Rich DH

series ordinal

2

1 reference

24 September 2017

publication date

1 August 1998

1 reference

Current Opinion in Chemical Biology

24 September 2017

published in

1 reference

24 September 2017

volume

2

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

441-452

1 reference

Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

The "One-Bead-One-Compound" Combinatorial Library Method

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Modern computational chemistry and drug discovery: structure generating programs

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Potent new inhibitors of human renin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Peptidomimetics derived from natural products

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Locating ligand-binding sites in 7TM receptors by protein engineering.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Design of potent and selective human cathepsin K inhibitors that span the active site

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Crystal structure of human cathepsin K complexed with a potent inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class of interleukin-1 beta-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

First examples of peptidomimetic inhibitors of interleukin-1 beta converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Ureido-based peptidomimetic inhibitor of herpes simplex virus ribonucleotide reductase: an investigation of inhibitor bioactive conformation.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Design, synthesis, and in vitro activities of benzamide-core glycoprotein IIb/IIIa antagonists: 2,3-diaminopropionic acid derivatives as surrogates of aspartic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on so

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

The crystal structure of human α‐thrombin complexed with LY178550, a nonpeptidyl, active site‐directed inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Amidino-substituted aromatic heterocycles as probes of the specificity pocket of trypsin-like proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Design and synthesis of potent and highly selective thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Ras farnesyltransferase: a new therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Farnesyltransferase as a target for anticancer drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

Matrix metalloproteinase inhibitors in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2898%2980119-1

7 January 2021

10.1016/S1367-5931(98)80119-1

Identifiers

DOI

1 reference

24 September 2017

1 reference